Free radical theory of aging: Beneficial effect of antioxidants on the life span of male NZB mice; role of free radical reactions in the deterioration of the immune system with age and in the pathogenesis of systemic lupus erythematosus

AGE

Volumn 3, Issue 3, 1980, Pages 64-73

  Harman, Denham ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CELL NUCLEUS ANTIGEN; ETHOXYQUIN; PHOSPHORIC ACID;

AGE; AGING; ANIMAL EXPERIMENT; AUTOIMMUNITY; BLOOD AND HEMOPOIETIC SYSTEM; ETIOLOGY; IMMUNITY; MOUSE; ORAL DRUG ADMINISTRATION; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMUS;

EID: 0018959702     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/BF02431730     Document Type: Article

References (90)

1. Immunobiology of aging: evaluation of current status
2. Autoimmunity, histocompatibility, and aging
3. Free radical theory of aging: nutritional implications
4. The free radical theory of aging: effect of age on serum copper levels
5. The free radical theory of aging: the effect of age on serum mercaptan levels
6. The effect of age and protein deprivation on the sulphydryl content of serum albumin
7. Cyclic nucleotide levels in resting and mitogen-stimulated spleen cell suspensions from young and old mice
8. Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine-3′, 5′-monophosphate
9. Oxidative activation of guanylate cyclase by prostaglandin endoperoxides and fatty acid hydroperoxides
10. Cyclic GMP metabolism and involvement in biological regulation
11. Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase by nitrosamines
12. Free radical theory of aging: effect of free radical reaction inhibitors on the immune response
13. Immunoregulatory circuits among T-cell sets. I. T-helper cells induce other T-cell sets to exert feedback inhibition
14. Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice
15. Immunological circuits: cellular composition
16. Aberrations of suppressor T-cells in human graft-versus-host-disease
17. Studies of allospecific suppressor cells in culture
18. In vitro generation of cells capable of suppressing in vitro cell-mediated immunity
19. Summing-up: immunological tolerance (suppression/deletion)
20. In vitro evaluation of radiation-induced augmentation of the immune response
21. The immunology and pathology of NZB mice
22. The pathogenesis of autoimmunity in New Zealand black mice
23. Autoimmune disease in mice
24. Spontaneous hemolytic anemia in mice of the NZB/BL strain
25. Dietary influence on breeding behavior, hemolytic anemia, and longevity in NZB mice
26. N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt: prevention of autoimmune kidney disease in NZB/NZW F, hybrid mice
27. Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism
28. Subpopulations of human T-lymphocytes. II. Effect of thymopoietin, corticosteroids, and irradiation
29. Effect of colchicine on the antibody response
30. Age-related changes in suppressor functions of human T-cells
31. Thymic involution: effect on T-cell differentiation
32. Selective loss of suppressor cell function in New Zealand mice induced by NTA
33. Differential cytotoxic effect of natural thymocytotoxic autoantibody of NZB mice on functional subsets of T-cells
34. Studies of immune function of patients with systemic lupus erythematosus
35. Synthesis of IgM by cells of NZB and SWR mice and their crosses
36. Genetic control of lymphocyte suppression. I. Lack of suppression in aged NZB mice is due to a B-cell defect
37. Demonstration of activation of B-lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM
38. Release of arachidonic acid from human lymphocytes in response to mitogenic lectins
39. Increased prostaglandin production by human monocytes after membrane receptor activation
40. Macrophage-mediated suppression. I. Evidence for participation of both hydrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation
41. Effects of glutathione-oxidizing agents on microtubule assembly and microtubule-dependent surface properties of human neutrophils
42. Acute responses to ionizing radiation
43. The clinical features of systemic lupus erythematosus
44. Pathology of immune complexes and systemic lupus erythematosus
45. Familial abnormalities of suppressor-cell function in systemic lupus erythematosus
46. UV-induced DNA to protein cross-linking in mammalian cells
47. Lupus erythematosus and porphyria
48. Serum copper levels in pregnancy and pre-eclampsia
49. Studies in copper metabolism. VII. Blood copper in pregnancy and various pathologic states
50. Effects of oral contraceptive agents on trace element metabolism-a review
51. Serum lipids in women on oral contraceptives
52. Oral contraceptives and exacerbation of lupus erythematosus
53. Rheumatic symptoms and serological abnormalities induced by oral contraceptives
54. Drug-induced autoimmune disease
55. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat
56. Metabolic activation of hydrazines to highly reactive hepatoxic intermediates
57. Metabolic activation of methyldopa by cytochrome P450-generated superoxide anion
58. The biochemistry and ultrastructure of the nuclear envelope
59. Nuclear aryl hydrocarbon hydroxylase and interaction of polycyclic hydrocarbons with nuclear components
60. Epoxide hydrase and mixed-function oxidase activities of rat liver nuclear membranes
61. Wild-type gross leukemia virus and the pathogenesis of the glomerulonephritis of New Zealand mice
62. Autoimmunity and neoplasia: the possible role of the C-type viruses
63. The virus hypothesis in systemic lupus erythematosus
64. C-type virus expression in systemic lupus erythematosus
65. Why cell biologists should be aware of genetically transmitted viruses
66. Mouse leukemia virus activation by chemical carcinogens
67. A leukemogenic filtrable agent from chemically-induced lymphoid leukemia in C57BL mice
68. Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus
69. Ultraviolet radiation-induced chromosomal abnormalities in fetal fibroblasts from New Zealand black mice
70. The biology and detection of immune complexes
71. Serum immune complexes and disease activity in lupus nephritis
72. The biochemistry of complement
73. Chemotactic factors and the neutrophil
74. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation
75. Mediators of immune complex-induced aggregation of polymorphonuclear neutrophils. I. C5a anaphylatoxin, neutrophil cationic proteins and their cleavage fragments
76. Effect of prostaglandins E1, E2, and F2a on neutrophil aggregation
77. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease
78. Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage
79. Elaboration of toxic oxygen by-products by neutrophils in a model of immune complex disease
80. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes: an in vitro model of immune vascular damage
81. Corticosteroids inhibit complement-induced granulocyte aggregation
82. Oxidative metabolism of the human eosinophil
83. Biotransformation and hepatotoxicity of halothane
84. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis
85. Cell-mediated immunity to liver antigen in toxic liver injury
86. The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: a case report
87. DL-2-oxo-3-(2-mercaptoethyl)-5-phenylimidazolidine. A sulfhydryl metabolite of levamisole that interacts with microtubules
88. Retinopathy following chloroquin therapy
89. Lupus erythematosus and vitamin E: an effective and nontoxic therapy